{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:52:20Z","timestamp":1790722340716,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Telethon","award":["GGP06019"],"award-info":[{"award-number":["GGP06019"]}]},{"name":"Telethon","award":["GGP09018"],"award-info":[{"award-number":["GGP09018"]}]},{"name":"Telethon","award":["GGP14014"],"award-info":[{"award-number":["GGP14014"]}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["602300"],"award-info":[{"award-number":["602300"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Progetti di Rilevante Interesse Nazionale","award":["2015F3JHMB"],"award-info":[{"award-number":["2015F3JHMB"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.bone.2018.02.031","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T20:26:41Z","timestamp":1520281601000},"page":"343-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["RNA interference therapy for autosomal dominant osteopetrosis type 2. Towards the preclinical development"],"prefix":"10.1016","volume":"110","author":[{"given":"Antonio","family":"Maurizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Capulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajvi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9105-1131","authenticated-orcid":false,"given":"Annabel","family":"Curle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Rucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5887-4419","authenticated-orcid":false,"given":"Anna","family":"Teti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2018.02.031_bb0005","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(15)60693-6","article-title":"Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management","volume":"385","author":"Woodruff","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bone.2018.02.031_bb0010","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/745043","article-title":"Precision medicine for continuing phenotype expansion of human genetic diseases","volume":"2015","author":"Yu","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bone.2018.02.031_bb0015","series-title":"Ophthalmology","article-title":"Fundamentals of human genetics","author":"Wiggs","year":"2014"},{"key":"10.1016\/j.bone.2018.02.031_bb0020","series-title":"Nelson Textbook of Pediatrics","article-title":"Patterns of genetic transmission","author":"Scott","year":"2016"},{"key":"10.1016\/j.bone.2018.02.031_bb0025","doi-asserted-by":"crossref","first-page":"33298","DOI":"10.1074\/jbc.M305207200","article-title":"Microtubule-dependent oligomerization of tau. Implications for physiological tau function and tauopathies","volume":"278","author":"Makrides","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2018.02.031_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.21","article-title":"Effective small interfering RNA therapy to treat CLCN7-dependent autosomal dominant osteopetrosis type 2","volume":"4","author":"Capulli","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.bone.2018.02.031_bb0035","first-page":"365","article-title":"R\u00f6ntgenbilder einer seltenen Knock-enerkrankung","volume":"5","author":"Albers-Sch\u00f6nberg","year":"1904","journal-title":"Munch Med Wochenscher"},{"key":"10.1016\/j.bone.2018.02.031_bb0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0014-5793(95)01298-2","article-title":"ClC-6 and ClC-7 are two novel broadly expressed members of the CLC chloride channel family","volume":"377","author":"Brandt","year":"1995","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bone.2018.02.031_bb0045","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nature06907","article-title":"The Cl\u2212\/H+ antiporter ClC-7 is the primary chloride permeation pathway in lysosomes","volume":"453","author":"Graves","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bone.2018.02.031_bb0050","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0002-9440(10)63712-1","article-title":"Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II","volume":"164","author":"Henriksen","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bone.2018.02.031_bb0055","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0002-9440(10)62269-9","article-title":"Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption","volume":"166","author":"Karsdal","year":"2005","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bone.2018.02.031_bb0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bone.2013.10.021","article-title":"Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models","volume":"59","author":"Alam","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.02.031_bb0065","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.abb.2014.06.017","article-title":"The great beauty of the osteoclast","volume":"558","author":"Cappariello","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bone.2018.02.031_bb0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(01)00206-9","article-title":"Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man","volume":"104","author":"Kornak","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.bone.2018.02.031_bb0075","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1038\/emboj.2011.137","article-title":"ClC-7 is a slowly voltage-gated 2Cl(\u2212)\/1H(+)-exchanger and requires Ostm1 for transport activity","volume":"30","author":"Leisle","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.bone.2018.02.031_bb0080","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1530\/EJE-13-0136","article-title":"Autosomal dominant osteopetrosis revisited: lessons from recent studies","volume":"169","author":"Bollerslev","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2018.02.031_bb0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00003086-199309000-00006","article-title":"Autosomal dominant osteopetrosis","volume":"294","author":"Bollerslev","year":"1993","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.bone.2018.02.031_bb0090","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1210\/jc.2006-1986","article-title":"Autosomal dominant osteopetrosis: clinical severity and natural history of 94 subjects with a chloride channel 7 gene mutation","volume":"92","author":"Waguespack","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bone.2018.02.031_bb0095","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1364\/JOSAA.1.000612","article-title":"Practical cone-beam algorithm","author":"Feldkamp","year":"1984","journal-title":"J. Opt. Soc. Am. A"},{"key":"10.1016\/j.bone.2018.02.031_bb0100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/clinchem\/46.3.431a","article-title":"Circadian variation in serum CrossLaps concentration is reduced in fasting individuals","volume":"46","author":"Christgau","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bone.2018.02.031_bb0105","series-title":"ACM SIGGRAPH Computer Graphics","first-page":"163","article-title":"Marching cubes: a high resolution 3d surface construction algorithm","volume":"21","author":"Lorensen","year":"1987"},{"key":"10.1016\/j.bone.2018.02.031_bb0110","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2018.02.031_bb0115","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1083\/jcb.200906014","article-title":"The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis","volume":"187","author":"Rucci","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bone.2018.02.031_bb0120","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/ilar.43.4.244","article-title":"Guidelines for the design and statistical analysis of experiments using laboratory animals","volume":"43","author":"Festing","year":"2002","journal-title":"ILAR J."},{"key":"10.1016\/j.bone.2018.02.031_bb0125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00003086-200008000-00032","article-title":"Serum creatine kinase isoenzyme BB in mammalian osteopetrosis","volume":"377","author":"Bollerslev","year":"2000","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.bone.2018.02.031_bb0130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.addr.2015.01.007","article-title":"Preclinical and clinical development of siRNA-based therapeutics","volume":"87","author":"Ozcan","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bone.2018.02.031_bb0135","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1358\/dof.2009.034.09.1413267","article-title":"Advances in systemic siRNA delivery","volume":"34","author":"Leng","year":"2009","journal-title":"Drugs Future"},{"key":"10.1016\/j.bone.2018.02.031_bb0140","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2017.02.002","article-title":"Osteopetroses, emphasizing potential approaches to treatment","volume":"102","author":"Teti","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2018.02.031_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/aja.1001610102","article-title":"The hematogenous origin of osteoclasts: experimental evidence from osteopetrotic (microphthalmic) mice treated with spleen cells from beige mouse donors","volume":"161","author":"Marks","year":"1981","journal-title":"Am. J. Anat."},{"key":"10.1016\/j.bone.2018.02.031_bb0150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00003086-198201000-00001","article-title":"The classic: osteopetrosis cured by temporary parabiosis","volume":"162","author":"Walker","year":"1982","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.bone.2018.02.031_bb0155","series-title":"Stem Cells and Bone Tissue. Chapter 15","first-page":"267","article-title":"Haematopoietic stem cell transplantation in autosomal recessive osteopetrosis","author":"Teti","year":"2013"},{"key":"10.1016\/j.bone.2018.02.031_bb0160","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bone.2018.02.031_bb0165","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000209473","article-title":"FDA requirements for preclinical studies","volume":"25","author":"McElvany","year":"2009","journal-title":"Front. Neurol. Neurosci."},{"key":"10.1016\/j.bone.2018.02.031_bb9000","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bone.2013.10.021","article-title":"Generation of the first autosomal dominant osteopetrosis type II (ADO2) disease models","volume":"59","author":"Alam","year":"2014","journal-title":"Bone."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328218300905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328218300905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T04:10:36Z","timestamp":1660536636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328218300905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":34,"alternative-id":["S8756328218300905"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2018.02.031","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA interference therapy for autosomal dominant osteopetrosis type 2. Towards the preclinical development","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2018.02.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}